kabutan

StemRIM(4599) Summary

4599
TSE Growth
StemRIM
295
JPY
-16
(-5.14%)
Jan 29, 3:30 pm JST
1.92
USD
Jan 29, 1:30 am EST
Result
PTS
outside of trading hours
Summary Chart Historical News Financial Result
PER
PBR
3.47
Yield
ー%
Margin Trading Ratio
Stock Price
Jan 29, 2026
Opening Jan 29, 9:00 am
309 JPY 2.01 USD
Previous Close Jan 28
311 JPY 2.03 USD
High Jan 29, 9:00 am
309 JPY 2.01 USD
Low Jan 29, 12:33 pm
294 JPY 1.92 USD
Volume
181,900
Trading Value
0.05B JPY 0.36M USD
VWAP
298.94 JPY 1.95 USD
Minimum Trading Value
29,500 JPY 192 USD
Market Cap
0.02T JPY 0.12B USD
Number of Trades
281
Liquidity & Number of Trades
As of Jan 29, 2026
Liquidity
Mid
1-Year Average
232
1-Year High Apr 4, 2025
1,107
Margin Trading
Date Short Interest Long Margin Positions Ratio
Jan 23, 2026 0 2,866,800
Jan 16, 2026 0 2,858,200
Jan 9, 2026 0 2,891,300
Dec 26, 2025 0 2,881,200
Dec 19, 2025 0 2,827,400
Company Profile
StemRIM is a biotech venture originating from Osaka University, developing "regeneration-inducing medicine" that promotes self-tissue regeneration.
Sector
Pharmaceuticals
StemRIM is a research and development-based pharmaceutical venture founded at Osaka University. The company is engaged in the research and development of its proprietary "regeneration-inducing medicine" that promotes self-tissue regeneration and healing. This technology aims to achieve effects equivalent to regenerative medicine without using living cells, instead activating patients' own internal stem cells through compound administration to function broadly against various diseases. The company's lead pipeline product, redasemtide, is currently undergoing clinical trials for epidermolysis bullosa and acute cerebral infarction. Additionally, StemRIM is advancing research and development in a wide range of regeneration-inducing medical technologies, including novel peptides for systemic and local administration, therapeutic autologous cell collection devices, and stem cell gene therapy. Through these technologies, StemRIM aims to overcome the challenges of conventional regenerative medicine and realize safer and more effective treatment methods.